Newscasting from EULAR 2024 - Frederic Lavie, MD, PhD: Guselkumab Demonstrates Rapid, Sustained Improvements in Severe PsA
Treatment with guselkumab led to rapid, clinically meaningful improvements in disease activity among patients with severe psoriatic arthritis (PsA), which were maintained through 2 years.
In an interview with HCPLive, Frederic Lavie, MD, PhD, head of Global Medical Affairs Rheumatology at the Janssen Pharmaceutical Companies of Johnson & Johnson, discussed the findings of an analysis of the DISCOVER-1 and DISCOVER-2 trials, which enrolled bio-naïve patients with active PsA.
Source: MDMag
To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.
